(Q38112092)

29 August 2017

title

Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

29 August 2017

main subject

1 reference

J Andrew Woods

1

1 reference

29 August 2017

Kimberly L Nealy

series ordinal

2

1 reference

29 August 2017

Robert W Barrons

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

4 June 2013

1 reference

Annals of Pharmacotherapy

29 August 2017

published in

1 reference

29 August 2017

volume

47

1 reference

29 August 2017

issue

7-8

1 reference

29 August 2017

page(s)

1017-1028

1 reference

Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects

29 August 2017

cites work

1 reference

Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials

21 January 2018

1 reference

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

21 January 2018

1 reference

Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease

21 January 2018

1 reference

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

21 January 2018

1 reference

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

21 January 2018

1 reference

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants

21 January 2018

1 reference

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

21 January 2018

1 reference

Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study

21 January 2018

1 reference

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial

21 January 2018

1 reference

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

21 January 2018

1 reference

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thien

21 January 2018

1 reference

Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs.

21 January 2018

1 reference

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients

21 January 2018

1 reference

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.

21 January 2018

1 reference

Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

21 January 2018

1 reference

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

21 January 2018

1 reference

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

21 January 2018

1 reference

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

21 January 2018

1 reference

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

The MCID of the transition dyspnea index is a total score of one unit

21 January 2018

1 reference

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

A one-year trial of tiotropium Respimat plus usual therapy in COPD patients

21 January 2018

1 reference

The safety of tiotropium--the FDA's conclusions

21 January 2018

1 reference

Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD.

21 January 2018

1 reference

Symptom variability in patients with severe COPD: a pan-European cross-sectional study

21 January 2018

1 reference

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1S002

1 reference

29 August 2017

1 reference